Clinical trials: Rosuvastatin
Primary Hypercholesterolemia
Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia
The purpose of this study is to evaluate efficacy and safety of HL140 in patients with primary hypercholesterolemia.
- Trial name
- NCT03571087
- Testing
- HL140 5/10, HL140 10/10, HL140 20/10
- Volunteers
- 374 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Dyslipidemia, Renal Insufficiency
Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly
Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly
- Trial name
- NCT00585143
- Testing
- ABT-335, Rosuvastatin
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Healthy
Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and Rosuvastatin
To investigate the mutual interaction potential of digoxin, furosemide, metformin, and rosuvastatin when given alone or together as a cocktail, and to investigate the effect of high doses of metformin or furosemide on…
- Trial name
- NCT02231931
- Testing
- Digoxin, Rosuvastatin, Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Heart Failure
GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHF
INTRODUCTION While pharmacological treatments specifically targeted to the cardio-circulatory system have been largely investigated, scanty controlled data are available concerning the role of dietary and metabolic approaches in…
- Trial name
- NCT00336336
- Testing
- n-3 PUFA, Rosuvastatin
- Where
- 337 sites in Italy, Switzerland
- Volunteers
- 6,975 people
- Sponsor
- Gruppo di Ricerca GISSI
Hypercholesterolemia, Dyslipidaemia
Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)
The purpose of this study is to compare the effect of 6 weeks of treatment with Rosuvastatin with 6 weeks of treatment with Atorvastatin in African American subjects with hypercholesterolemia.
- Trial name
- ARIES (NCT00653744)
- Testing
- Rosuvastatin, Atorvastatin
- Volunteers
- 1,700 people
- Sponsor
- AstraZeneca
Hepatitis C
Rosuvastatin for Hepatitis C
Objective: Determine if maximum doses of rosuvastatin are safe in patients infected with hepatitis C and if the so called pleiotropic effects of rosuvastatin cause a decrease in the HCV viral load. Primary study parameters: 1.
- Trial name
- NCT00371579
- Testing
- rosuvastatin
- Where
- Netherlands
- Sponsor
- UMC Utrecht
Healthy Male Volunteer
The Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers
To investigate the pharmacokinetic Drug-drug interaction
- Trial name
- NCT02233218
- Testing
- Telmisartan, Amlodipine, Rosuvastatin
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy
Clinical Trial to Compare the Pharmacokinetics of DP-R208
A randomized, single-dose, open, crossover clinical trial to compare the pharmacokinetics of DP-R208 (Candesartan cilexetil and Rosuvastatin calcium fixed dose combinations) in comparison to each component administered alone in…
- Trial name
- NCT02707224
- Testing
- DP-R208, Candesartan cilexetil, Rosuvastatin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alvogen Korea
Hypercholesterolemia
Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia
Recently, research studies have shown that patients who have had trouble taking statins every day, are able to take statins if they take them only once or twice a week.
- Trial name
- NCT00972829
- Testing
- Rosuvastatin, Ezetimibe
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Bronx VA Medical Center
Metabolic Disease
Safety, Tolerability and PK of PXL770 in Healthy Male Subjects
PXL770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (AMPK) being developed by Poxel S.A. for the treatment of type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03395470
- Testing
- PXL770, Rosuvastatin
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Poxel SA
Dyslipidaemia
48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety
The purpose of this study is to assess the efficacy and safety of rosuvastatin in reducing low density lipoprotein cholesterol levels to internationally recognised goals in subjects with dyslipidaemia.
- Trial name
- NCT00654602
- Testing
- Rosuvastatin, Maintenance of specific diet
- Volunteers
- 1,500 people
- Sponsor
- AstraZeneca
Hypertension, Hyperlipidemia
Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan
The objective of this study is to compare pharmacokinetics after single oral administration of rosuvastatin and valsartan each separately versus coadministration of rosuvastatin and valsartan in healthy male volunteers.
- Trial name
- NCT01609907
- Testing
- Rosuvastatin+Valsartan (Sequence 1), Rosuvastatin+Valsartan (Sequence 2), Rosuvastatin+Valsartan (Sequence 3)
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Essential Hypertension, Dyslipidemia
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia
The purpose of this study is to evaluate the efficacy and safety of combination of Fimasartan/Rosuvastatin in comparison to each component administered alone in patients with essential hypertension and dyslipidemia.
- Trial name
- NCT02166814
- Testing
- Fimasartan and Rosuvastatin, Fimasartan, Rosuvastatin
- Where
- 26 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Prostate Cancer
A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer
The primary purpose of this study is to determine the effect of multiple once daily administrations of enzalutamide on the pharmacokinetics of a single dose of digoxin (P-glycoprotein (P-gp) substrate) and rosuvastatin (breast…
- Trial name
- NCT04094519
- Testing
- enzalutamide, digoxin, rosuvastatin
- Where
- Moldova
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Hypertension,, Hyperlipidemia
Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia
This study aims to evaluate the efficacy and safety of the coadministration of valsartan (Diovan®) 160mg and rosuvastatin (Crestor®) 20mg in comparison to each component administered alone in patients with hypertension and…
- Trial name
- NCT01918332
- Testing
- Valsartan 160mg, Rosuvastatin 20mg
- Where
- South Korea
- Volunteers
- 168 people
- Sponsor
- LG Life Sciences
Coronary Artery Disease, Dyslipidemias
Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)
the investigators would like to compare the differences between roschvastin and atovastatin in patients who require high-dose statin/ejetimib to undergo a new generation of drug elution stent implantation for cardiovascular…
- Trial name
- NCT05910476
- Testing
- a high dose of statin/ezetimib
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Yonsei University
Hypercholesterolemia, HIV Infections
Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets
This study involves comparing the effectiveness of treatments in HIV positive patients who may be predisposed to heart attack or stroke.
- Trial name
- NCT00908011
- Testing
- Ezetimibe, Rosuvastatin (standard care)
- Where
- Canada
- Volunteers
- 43 people
- Sponsor
- University of British Columbia
Left Ventricular Diastolic Dysfunction, Hyperlipidemias
Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia
preserved left ventricular ejection fraction (LVEF ≥ 50%) and are accompanied by dyslipidemia (LDL ≥ 100 mg / dl) will be enrolled. Only patients who do not meet the exclusion criteria should be enrolled in the study.
- Trial name
- NCT04433533
- Testing
- Rosuvastatin 20, Rosuvamibe 10/10
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Yonsei University
Breast Cancer
Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer
Research studies have shown a strong association between cancer and blood clots in the veins (also known as deep vein thrombosis).
- Trial name
- NCT01299038
- Testing
- rosuvastatin
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center
Primary Hypercholesterolemia
Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting
This study assessed the safety and efficacy of generic Rosuvastatin in reducing plasma low density lipoprotein (LDL) cholesterol in Lebanese adult patients (18 years or older) with dyslipidemia for both primary and secondary…
- Trial name
- NCT03516955
- Testing
- Rosuvastatin
- Volunteers
- 317 people
- Sponsor
- Hikma Pharmaceuticals LLC